The following is excerpted from the question-and-answer section of the transcript.
(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)
Question: Matt Hewitt - Craig-Hallum Capital Group LLC - Analyst
: Good afternoon and thank you for taking the questions. Maybe first one regarding the landscape. Obviously, we've been hearing not just from you
guys on your Q4 call, but today and we've heard from others that it's just a really difficult environment right now.
Pharma and biotech companies are facing funding pressures. There're all sorts of issues, what are you hearing from your customers as far as these
cancellations are concerned? It sounds like it's coming down, but is that a function of them reprioritizing pipelines?
Is it a function of kind of shifting gears and maybe exiting one area to focus on something else, and that's what this next leg is going to be? Or is
there something else driving the I guess, what's in improving bookings situation?
Question: Matt Hewitt - Craig-Hallum Capital Group LLC - Analyst
: Got it. So maybe more back to a more normalized of capital. That's super helpful. And then, question regarding the gross margin, some of the
decline year on year was due to increased outsourcing that you guys are doing. Are those are any of those services something that in theory you
guys could bring in-house at some point, to reduce your dependence on others to complete some of these studies?
REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us
consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.
SEPTEMBER 13, 2023 / 8:30PM, CSBR.OQ - Q1 2024 Champions Oncology Inc Earnings Call
Question: Matt Hewitt - Craig-Hallum Capital Group LLC - Analyst
: Got it. And then maybe one last one for me and I'll hop back into queue. I think you were commenting on the Biomarkers and some of the key hires
that you're able to get there. You've seen an increase in lead gen and your clinical bookings are improving.
How should we thinking about size of some of those types of studies? Are they bigger than your historical studies or, just I know it's they've got a
longer lead time. So, I'm just thinking theoretically, those should be larger right.
Question: Matt Hewitt - Craig-Hallum Capital Group LLC - Analyst
: That's great. Thank you.
Question: David Baron - Baron Capital, Inc. - Analyst
: Good afternoon, Morris. I wanted to ask you a question about your hiring. I know that it's out there that the Champions is looking to hire. Are your
results affecting your hiring goals, are your hiring goals increasing or decreasing? Are these positions you are looking to fill, more for entry level,
or higher-level management, in which you're seeking more seasoned employees?
REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us
consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.
SEPTEMBER 13, 2023 / 8:30PM, CSBR.OQ - Q1 2024 Champions Oncology Inc Earnings Call
Question: David Baron - Baron Capital, Inc. - Analyst
: Thank you.
|
